Craig Anthony Portell, MD

Unless otherwise indicated, this information has been self-reported and has not been verified by the Board of Medicine.

Loyola University Chicago Stritch School Of Medicine - Maywood IL
Rank: Instructor
Years: 2010-2011

University Of Virginia School Of Medicine - Charlottesville VA
Rank: Associate Professor
Years: 2013-Present

None Reported

Orbital mantle cell lymphoma presenting as myasthenia gravis
Orbit
Volume: 36
Date: 01 2017

Novel Therapies for Relapsed/Refractory Mantle Cell Lymphoma
Best Practicies and Research in Clinical Haematology
Volume: 31
Date: 01 2018

Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome when Initiating Venetoclax in Patients with Mantle Cell Lymphoma
Journal of Clinical Oncology
Volume: 36
Date: 01 2018

Risk of Major Bleeding with Ibrutinib
Clinical Lymphoma, Myeloma and Leukemia
Volume: 18
Date: 01 2018

The Phase 3 DUO trial: duvelisib versus ofatumumab in relapsed and refractory CLL/SLL
Blood
Volume: 132
Date: 01 2018

Maintenance Rituximab or Observation after Frontline Treatment with Bendamustine-Rituximab for Follicular lymphoma
British Journal of Haematology
Volume: 184
Date: 01 2019

Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma with Alectinib
Clinical Lymphoma, Myeloma and Leukemia
Volume: 19
Date: 06 2019

Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy
Clinical Cancer Research
Volume: 26
Date: 01 2020

Burkitt Lymhpoma in the Modern Era: Real World Outcomes and Prognostication Across 30 US Cancer Centers
Blood
Volume: epub
Date: 01 2020

Outcomes in Aggressive B-cell Non-Hodgkin Lymphoma Patients Following Intensive Front-Line Treatment Failure
Cancer
Volume: 126
Date: 01 2020